Oncotelic, formerly traded under the name Mateon (MATN), is an American firm working in India for the treatment of Covid-19. The firm ended their OT-101 trial against Covid in the summer of 2021. This resulted in a drop in share price of approximately 25% over the course of the ensuing weeks. OT-101 and Arti-19 are TGF-Beta inhibitors. The firm has seen an increase in TGF-B in patients with symptomatic Covid and have developed a theory that TGF-Beta is important in the replication of the virus. Blocking TGF-Beta would then decrease viral replication and clinical worsening if the firm’s theory could be shown to be accurate. Arti-Veda (Indian brand name) and Arti-Shield (the name used outside of India) are being sold as part of a package of products under the combined name PulmoHeal. The drug Arti-Veda/Arti-Shield is being tested in the Arti-19 trial and has been accepted by the ministry of AYUSH. The firm has developed partnerships with Chopra and focused on addressing the pandemic among India’s 1.2 billion inhabitants.
